Trametinib Slows Recurrent Low-Grade Serous Ovarian Carcinoma
WEDNESDAY, Feb. 9, 2022 -- Trametinib may be a new option for standard-of-care treatment for recurrent low-grade serous ovarian carcinoma, according to a study published online Feb. 5 in The Lancet.
David M. Gershenson, M.D., from the University of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Ovarian Cancer | Ovaries | Pharmaceuticals | Serous Carcinoma | Study